Home/Pipeline/GLP-1 variants

GLP-1 variants

Obesity

DiscoveryActive

Key Facts

Indication

Obesity

Phase

Discovery

Status

Active

Company

Heligenics

About Heligenics

Heligenics is a private, pre-revenue biotech platform company pioneering a genetics-inspired approach to biologic drug discovery. Its core innovation is the GigaAssay™, a high-throughput, cell-based screening platform capable of analyzing hundreds of thousands of biologic variants simultaneously to map function and identify optimized drug candidates. The company has generated a substantial preclinical pipeline focused on interferon biobetters for autoimmune diseases and cancer, and is actively developing GLP-1 variants for the metabolic disorder space. Heligenics operates primarily through partnerships with pharmaceutical and biotechnology companies to advance and license its discovered assets.

View full company profile

Therapeutic Areas

Autoimmune Disease Cancer Metabolic disorder

Other Obesity Drugs

Drug	Company	Phase	Status
LET003	Harbour BioMed	Discovery	Active (Global)
LET001	Harbour BioMed	Discovery	Active (Global)
RGT-075	Regor Therapeutics	Phase 2b	Active
Anti‑Obesity Oral Drug	Premas Biotech	Phase 1	Active
Obesity Target Discovery Collaboration	Fauna Bio	Target Discovery/Preclinical	Active
MYO Platform (Metabolic Disease)	Renbio	Pre-clinical	Active
Obesity Clinical Trials	IMA Clinical Research	Not Applicable (Service)	Active
KAYO-2000	KayoThera	Preclinical	Active
MVD-1 (SANA)	Eolo Pharma	Phase 1	Active
GIP-neutralizing antibody	Helicore Biopharma	Pre-clinical	Active
Antral Gastroplasty / Endoscopic Sleeve	Endo-TAGSS	Pre-clinical	Active
Undisclosed siRNA Programs	Moonwalk Biosciences	Pre-clinical	Active